Claims for Patent: 9,867,822

Summary for Patent: 9,867,822

Title:	Cannabinoid receptor modulators
Abstract:	Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor; ##STR00001##
Inventor(s):	Thatte; Jayant (San Diego, CA), Blackburn; Anthony C. (San Diego, CA), Han; Sangdon (San Diego, CA), Jones; Robert M. (San Diego, CA), Jung; Jae-Kyu (San Diego, CA), Montalban; Antonio Garrido (San Diego, CA), Pal; Biman B. (San Diego, CA), Rueter; Jaimie Karyn (San Diego, CA), Strah-Pleynet; Sonja (Newton, MA), Thoresen; Lars (San Diego, CA), Xiong; Yifeng (San Diego, CA), Yue; Dawei (San Diego, CA), Zhu; Xiuwen (San Diego, CA)
Assignee:	Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	15/279,576
Patent Claims:	1. A composition comprising a compound which is: ##STR00062## and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents. 2. The composition of claim 1, wherein the compound is an anhydrous crystalline form of: ##STR00063## 3. The composition according to claim 1, wherein the analgesic agent is chosen from non-opioid drugs, opioid drugs, and co-analgesic medications. 4. The composition according to claim 3, wherein the non-opioid drug is chosen from non steroidal anti-inflammatory agents, choline magnesium trisalicylate, sulfasalazine, olsalazin, phenacetin, tenoxicam, phenylbutazone, oxyphenthartazone, tapentadol, celecoxib, etoricoxib, lumiracoxib, rofecoxib, parecoxib, and ziconotide. 5. The composition according to claim 4, wherein the non steroidal anti-inflammatory agent is chosen from acemetacin, acetaminophen, aminoprofen, aspirin, benoxaprofen, bucloxic acid, carprofen, choline magnesium salicylate, choline salicylate, clidanac, diclofenac, diflunisal, difluri sal, etodolac, fenoprofen, fenoprofen calcium, fentiazac, flosulide, flubufen, flufenamic acid, flufenisal, flurbiprofen, fluprofen, ibuprofen, indoprofen, indomethacin, isoxicam, ketoprofen, ketorolac tromethamine, lornoxicam, magnesium salicylate, meclofenamic acid, meclofenamate sodium, mefenamic acid, meloxicam, muroprofen, nabumetone, naproxen, nepafenac, niflumic acid, nimesulide, oxaprozin, oxpinac, piroprofen, piroxicam, pramoprofen, ramifenazone, sal salate, salicyl salicylic acid, sodium salicylate, sudoxicam, sulindac, suprofen, tiaprofenic acid, tiopinac, tolfenamic acid, tolmetin, trioxaprofen, zidometacin, and zomepirac. 6. The composition according to claim 3, wherein the opioid drug is chosen from: alfentanil, allylprodine, alphaprodine, anileridine, apomorphine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dextropropoxyphene, dezocine, diampromide, diamorphone, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dilaudid, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodeine, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, 6-monoacetylmorphine, morphine, morphine-6-glucuronide, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, noscapine, opium, oxycodone, oxymorphone, papavereturn, papverine, pentazocine, pethidine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, and tramadol. 7. The composition according to claim 1, wherein the analgesic agent comprises an NSAID and an opioid drug. 8. The composition according to claim 1, wherein the analgesic agent is chosen from vicodin, percocet, norco, lorcet, darvocet, and percodan. 9. The composition according to claim 1, wherein the analgesic agent is a coanalgesic medication chosen from antidepressants, anti-anxiety medications, migraine medications, and gabapentin. 10. The composition according to claim 1, wherein the anticancer agent is chosen from eribulin mesylate, cabazitaxel, sipuleucel-T, degarelix, raloxifene, topotecan hydrochloride, ixabepilone, lapatinib, erlotinib, gefitinib, abarelix, leuprolide acetate, fulvestrant, letrozole, triptorelin pamoate, herceptin, nolvadex, photofrin, xeloda, letrozole, anastrozole, flutamide, gemcitabine HCl, docetaxel, goserelin acetate, bevacizumab, celecoxib, cetuximab, denosumab, ibandronic acid, thyrotropin alfa, trabectedin, and pemetrexed. 11. The composition according to claim 1, wherein the osteoarthritis agent is chosen from valdecoxib, meloxicam, etodolac, naproxen sodium, diacerhein, tetracycline, antimalarial therapies, Gen-S, JNJ-39439335, JNJ-42160443, JNS013, N-[5-tert-butyl-2,3-dihydro-1H-inden-1(R)-yl]-N''(1H-indazol-4yl)urea, SAR114137, MEDI-578, LY545694, 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydr- o-3-hydroxy-6-methoxy-.alpha.-methyl-(.alpha.S,5.alpha.,7.alpha.)-hydrochl- oride, GRC 15300, benzamide, 3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl- ]-N,4-dimethyl-, ADX71943, ELI-216, 1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-, diractin, XEN 402, CRB 0022, apitoxin, and etoricoxib. 12. The composition according to claim 1, further comprising a pharmaceutically acceptable carrier. 13. A pharmaceutical product selected from: a pharmaceutical composition, a formulation, a dosage form, a combined preparation, a twin pack, and a kit; comprising a compound which is: ##STR00064## and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents. 14. A method for preparing a composition comprising the step of admixing a compound which is: ##STR00065## and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents. 15. A method for the treatment of pain in an individual in need thereof, comprising administering to said individual, a therapeutically effective amount of a compound which is: ##STR00066## and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents; wherein the pain is chosen from: bone and joint pain, pain associated with osteoarthritis, hyperalgesia, allodynia, inflammatory pain, inflammatory hyperalgesia, neuropathic pain, neuropathic hyperalgesia, acute nociception, muscle pain, dental pain, migraine and other headache pain, pain that occurs as an adverse effect of therapeutics in an individual, and pain associated with a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and an autoimmune condition. 16. A method of modulating the activity of the cannabinoid CB2 receptor comprising contacting the cannabinoid CB.sub.2 receptor with a composition comprising a compound selected from compounds of Formula Ia and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof: ##STR00067## wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are each independently selected from: H and C.sub.1-C.sub.6 alkyl; X is NR.sup.7 and Y is CC(O)N(R.sup.8)R.sup.9; or X is CC(O)N(R.sup.8)R.sup.9 and Y is NR.sup.7; R.sup.7 is --R.sup.10--R.sup.11 --R.sup.12--R.sup.13; wherein: R.sup.10 is absent; R.sup.11 is absent; R.sup.12 is absent; and R.sup.13 is selected from: C.sub.1-C.sub.6 alkyl, aryl, C.sub.3-C.sub.7 cycloalkyl, heteroaryl, heterocyclyl, and hydroxyl; wherein said C.sub.1-C.sub.6 alkyl, aryl, and heteroaryl are each optionally substituted with one or two substituents selected from: C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6 alkylsulfonyl, amino, C.sub.3-C.sub.7 cycloalkyl, cyano, C.sub.2-C.sub.8 dialkylamino, C.sub.1-C.sub.6 haloalkyl, halogen, and hydroxyl; R.sup.8 is --R.sup.14--R.sup.15--R.sup.16--R.sup.17; wherein: R.sup.14 is selected from: C.sub.1-C.sub.6 alkylene, C.sub.3-C.sub.7 cycloalkenylene, C.sub.3-C.sub.7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said C.sub.1-C.sub.6 alkylene and heterocyclylene are each optionally substituted with one or more substituents selected from: C.sub.1-C.sub.6 alkoxycarbonyl, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, aryl, carboxy, heteroaryl, heterocyclyl, and hydroxyl; wherein said C.sub.1-C.sub.6 alkyl and aryl are optionally substituted with one substituent selected from: C.sub.1-C.sub.6 alkoxy, aryl, halogen, heteroaryl, and hydroxyl; or R.sup.14 is absent; R.sup.15 is selected from: --C(O)NH--, --C(O)--, --C(O)O--, C.sub.1-C.sub.6 alkylene, C.sub.3-C.sub.7 cycloalkylene, heteroarylene, and heterocyclylene; wherein said heterocyclylene is optionally substituted with C.sub.1-C.sub.6 alkyl; or R.sup.15 is absent; R.sup.16 is C.sub.1-C.sub.6 alkylene; or R.sup.16 is absent; and R.sup.17 is selected from: H, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6 alkylcarboxamide, C.sub.2-C.sub.6 alkynyl, ureyl, amino, aryl, arylamino, arylcarbonyl, aryloxy, carbo-C.sub.1-C.sub.6-alkoxy, carboxamide, carboxy, cyano, C.sub.3-C.sub.7 cycloalkyl, C.sub.5-C.sub.11 bicycloalkyl, C.sub.3-C.sub.7 cycloalkylamino, C.sub.2-C.sub.8 dialkylamino, C.sub.2-C.sub.8 dialkylsulfonamide, C.sub.1-C.sub.6 haloalkyl, heteroaryl, heteroaryloxy, heterobicyclyl, heterocyclyl, hydroxyl, and phosphonooxy; wherein said C.sub.1-C.sub.6 alkylamino, amino, aryl, arylamino, aryloxy, C.sub.5-C.sub.11 bicycloalkyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.3-C.sub.7 cycloalkylamino, heteroaryl, heterobicyclyl, heterocyclyl, and ureyl are each optionally substituted with one or more substituents selected from: C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkoxycarbonyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkylsulfonyl, amino, aryl, carboxy, cyano, C.sub.3-C.sub.7 cycloalkyl, C.sub.2-C.sub.8 dialkylamino, C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 haloalkyl, halogen, heteroaryl, heterocyclyl, and hydroxyl; and R.sup.9 is selected from: H, C.sub.1-C.sub.6 alkyl, and C.sub.3-C.sub.7 cycloalkyl; or R.sup.8 and R.sup.9 together with the nitrogen atom to which they are both bonded form a group selected from: heterocyclyl and heterobicyclyl, each optionally substituted with one or more substituents selected from: Carbo-C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, aryl, carbo-C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6 haloalkyl, halogen, heteroaryl, heteroaryloxy, heterocyclyl, and hydroxyl; wherein said aryl, C.sub.1-C.sub.6 alkyl, and heteroaryl are optionally substituted with one substituent selected from: C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, halogen, and hydroxyl, and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents. 17. The method according to claim 16, wherein the compound of Formula Ia is: ##STR00068## 18. The method of claim 16, wherein the compound of Formula Ia is an anhydrous crystalline form of: ##STR00069##

Details for Patent 9,867,822

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	THYROGEN	thyrotropin alfa	For Injection	020898	11/30/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26